KMT2D and acute myeloid leukemia: Specifically, in comparison with the control group, Kmt2d‐deficient AML cells exhibited 6680, 2592, and 1486 significantly lower H3K4me1, H3K4me2, and H3K27ac modified peaks, respectively (p < 0.05, log2‐fold change < −1; Figure S4B and Table S4, Supporting Information).